Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street estimates.

Key Takeaways A new daily pill helped people lose an average of 27 poundsThe pill may be easier to make and use than injectable weight loss drugsSide effects were mostly stomach-related, like vomiting ...

In May, it announced it would acquire SiteOne Therapeutics, a drugmaker with a promising investigational medicine for pain.

Good morning. Today, we read about the implications of mRNA funding cuts on national security, see layoffs at gene-editing ...

The Trump administration has been talking to drugmakers about ways to raise prices of medicines in Europe and elsewhere to ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...

Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...

Eli Lilly said it plans to submit the pill to the Food and Drug Administration for approval as a weight loss medication this ...

Eli Lilly stock falls 14% after new obesity drug underwhelms in clinical trial. Analysts maintain Buy rating, citing strong ...

This episode of Pharma Pulse covers Bayer’s $2.3 billion cost-cutting overhaul, promising Phase III results for Eli Lilly’s oral GLP-1 therapy orforglipron, and a pivotal court decision clearing the ...

* U.S. President Donald Trump has the so-called 'BRIC' group of nations directly in his trade war crosshairs, slapping ...